TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18507832

Group type: EXPERIMENTAL
Intervention: Amoxicillin and Omeprazole (OA)
Number of subjects: 770

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Triple therapy with OA and CLR (OAC)
Number of subjects: 770
Study: 17073704

Group type: EXPERIMENTAL
Intervention: Prostanoids (e.g., PGE(1)) used for treatment of peripheral arterial disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irbesartan and simvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8-iso-PGF(2alpha) in serum
Number of subjects: 0
Study: 14637328

Group type: EXPERIMENTAL
Intervention: Dieters
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-dieters
Number of subjects: 40
Study: 11071802

Group type: EXPERIMENTAL
Intervention: Stent implantation (AVE microstent, lengths 18-39 mm)
Number of subjects: 96

Group type: COMPARATOR
Intervention: PTCA (no stent)
Number of subjects: 96
Study: 8930429

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 14621749

Group type: EXPERIMENTAL
Intervention: Vasodilator drugs during organ procurement
Number of subjects: 31

Group type: COMPARATOR
Intervention: Dopamine (greater than 4 microg/kg per min)
Number of subjects: 31
Study: 30161045

Group type: EXPERIMENTAL
Intervention: Ptosis repair (levator resection)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Lower levator function (LF)
Number of subjects: 78
Study: 26564102

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 mL/d) for 21 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline) for 21 days
Number of subjects: 0
Study: 26571321

Group type: EXPERIMENTAL
Intervention: 980-nm diode laser vaporization (PVP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both PVP and TURP
Number of subjects: 72
Study: 23547851

Group type: EXPERIMENTAL
Intervention: Azithromycin and levamisole (Group 1)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Azithromycin alone (Group 2)
Number of subjects: 169
Study: 20508185

Group type: EXPERIMENTAL
Intervention: Virtual reality using Nintendo Wii gaming system (VRWii)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Recreational therapy (playing cards, bingo, or 'Jenga')
Number of subjects: 22
Study: 17898015

Group type: EXPERIMENTAL
Intervention: Septoplasty (surgery group; 27 patients)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham surgery (placebo group; 22 patients)
Number of subjects: 49
Study: 16873669

Group type: EXPERIMENTAL
Intervention: R-CHOP induction (R: 375 mg/m² intravenously, day 1)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: R maintenance (375 mg/m² intravenously once every 3 months for a maximum of 2 years)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: R-CHOP induction
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: CHOP induction
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: R maintenance
Number of subjects: 465
Study: 14608138

Group type: EXPERIMENTAL
Intervention: In-hospital initiation of cardiovascular protective medications (including antiplatelet therapy, beta-blockers, ACE inhibitors, and lipid-lowering therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (conventional care without in-hospital initiation)
Number of subjects: 0
Study: 11067793

Group type: EXPERIMENTAL
Intervention: 125 microgram dofetilide
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: 250 microgram dofetilide
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: 500 microgram dofetilide
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Dofetilide (all dosages)
Number of subjects: 325
Study: 8872627

Group type: EXPERIMENTAL
Intervention: Regression Method
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Catheter Method
Number of subjects: 6
Study: 1634926

Group type: EXPERIMENTAL
Intervention: Thiotepa (75 mg/m2) + GM-CSF (10 micrograms/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Thiotepa (75 mg/m2) + GM-CSF (5 micrograms/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Thiotepa (75 mg/m2) + GM-CSF (10 or 5 micrograms/kg)
Number of subjects: 13
Study: 6202572

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31352424

Group type: EXPERIMENTAL
Intervention: Primary Palliative Care Education, Training and Technical Support (PRIM-ER)
Number of subjects: 300000
Study: 29117063

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 111

Group type: COMPARATOR
Intervention: Nondexmedetomidine
Number of subjects: 111
Study: 26859707

Group type: EXPERIMENTAL
Intervention: Long-term training (LTT) for 5 days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Short-term training (STT) for 30 minutes
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 34
Study: 25370364

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy for Obesity (CRT‐O)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 90
Study: 23040775

Group type: EXPERIMENTAL
Intervention: Prone position in ARDSexp group (n=10)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Prone position in ARDSp group (n=11)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Supine position in ARDSp group (n=9)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Supine position in ARDSexp group (n=11)
Number of subjects: 41
Study: 19833893

Group type: EXPERIMENTAL
Intervention: Dietary weight loss (WL)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Dietary weight loss and moderate‐intensity aerobic exercise (WL+EX)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 59
Study: 16231038

Group type: EXPERIMENTAL
Intervention: Dietary fat restriction
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Increased exercise
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Moderate or substantial exercise increase with fat restriction
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Exercise increases at all levels of dietary fat change
Number of subjects: 962
Study: 12740277

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional treatment (no BPS)
Number of subjects: 43
Study: 11049203

Group type: EXPERIMENTAL
Intervention: Sodium selenite 200 microg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9291243

Group type: EXPERIMENTAL
Intervention: Eptifibatide (INTEGRILIN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8450730

Group type: EXPERIMENTAL
Intervention: Mouthpiece-breathing valve apparatus (MP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Respiratory face mask (MASK)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Running without respiratory apparatus (NOR)
Number of subjects: 17
Study: 3468598

Group type: EXPERIMENTAL
Intervention: Effervescent vitamin C preparations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Effervescent calcium preparations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin C preparations (excess consumption)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No mechanical cleaning
Number of subjects: 0
Study: 31883933

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided supraclavicular brachial plexus block (BPB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No regional anesthesia (control group)
Number of subjects: 80
Study: 29943185

Group type: EXPERIMENTAL
Intervention: MRI-guided transurethral ultrasound ablation (TULSA)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Delayed thermal ablation volume (DTAV, 240 cumulative equivalent minutes at 43°C)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Immediate post-treatment non-perfused volume (NPV)
Number of subjects: 29
Study: 27928711

Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS) with bioimpedance-guided protocol
Number of subjects: 250

Group type: COMPARATOR
Intervention: Clinical assessment (control)
Number of subjects: 250
Study: 25936187

Group type: EXPERIMENTAL
Intervention: High negative pressure drainage (60 kPa)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Low negative pressure drainage (30 kPa)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: High negative pressure drainage (60 kPa) after 3 days
Number of subjects: 74

Group type: COMPARATOR
Intervention: Low negative pressure drainage (30 kPa) after 3 days
Number of subjects: 74
Study: 24084627

Group type: EXPERIMENTAL
Intervention: Flow reversal
Number of subjects: 40

Group type: COMPARATOR
Intervention: Filter protection
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 21747837

Group type: EXPERIMENTAL
Intervention: Oral zinc sulfate (10 mg/kg/day for 45 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Systemic meglumine antimoniate (20 mg/kg/day intramuscularly for 20 days)
Number of subjects: 100
Study: 19151786

Group type: EXPERIMENTAL
Intervention: Haematopoietic cell transplantation (HCT)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: HCT
Number of subjects: 138

Group type: COMPARATOR
Intervention: CT
Number of subjects: 138
Study: 17250728

Group type: EXPERIMENTAL
Intervention: Combination of mirtazapine 4.5 mg and ibuprofen 400 mg
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Mirtazapine 4.5 mg
Number of subjects: 93
Study: 15899956

Group type: EXPERIMENTAL
Intervention: GH treatment 25.0 microg/kg.d
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: GH treatment 12.5 microg/kg.d
Number of subjects: 66

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 66
Study: 12575233

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (two 5-minute cycles of ischemia followed by 5-minute reperfusion)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (Group I)
Number of subjects: 16
Study: 10321443

Group type: EXPERIMENTAL
Intervention: Indapamide 1.25 mg daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low-salt diet (<100 mmol/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of indapamide and low-salt diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7624262

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2197755

Group type: EXPERIMENTAL
Intervention: Dietary treatment for hyperlipidemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug treatment for hyperlipidemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined therapies for hyperlipidemia
Number of subjects: 0
Study: 403549

Group type: EXPERIMENTAL
Intervention: Marijuana (500 mg cigarette containing 2.1% delta9-THC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo cigarette
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Marijuana (second phase)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Marijuana (group M-P)
Number of subjects: 40
Study: 31702120

Group type: EXPERIMENTAL
Intervention: ACBMNC infusion (5 × 10^7 cells/kg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 31
Study: 29121359

Group type: EXPERIMENTAL
Intervention: 577‐nm yellow laser (YL‐577)
Number of subjects: 92

Group type: COMPARATOR
Intervention: 532‐nm green laser (GL‐532)
Number of subjects: 92
Study: 25933707

Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Endocem
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cavity type (class I, II, III vs class V)
Number of subjects: 46
Study: 24069775

Group type: EXPERIMENTAL
Intervention: Shortened postpartum course of magnesium sulphate (two doses of intramuscular magnesium sulphate given four hours apart)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard Pritchard regimen of magnesium sulphate
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Shortened postpartum course of magnesium sulphate
Number of subjects: 98
Study: 21599928

Group type: EXPERIMENTAL
Intervention: Fesoterodine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Solifenacin
Number of subjects: 0
Study: 19891687

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% foam applied twice daily for up to 2 weeks on psoriatic skin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% foam applied once daily for up to 4 weeks on psoriatic skin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% foam applied once daily for 4 weeks on healthy skin
Number of subjects: 40
Study: 16721238

Group type: EXPERIMENTAL
Intervention: Russell‐Taylor Recon Nail
Number of subjects: 34

Group type: COMPARATOR
Intervention: Howmedica Long Gamma Nail
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 34
Study: 14687248

Group type: EXPERIMENTAL
Intervention: Amoxicillin 875 mg plus clavulanic acid 125 mg b.i.d., clarithromycin 500 mg b.i.d., omeprazole 20 mg b.i.d. (ACCO)
Number of subjects: 60
Study: 11572293

Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 46

Group type: COMPARATOR
Intervention: Fuji II LC
Number of subjects: 46
Study: 9562690

Group type: EXPERIMENTAL
Intervention: Novel adjuvant system (SBAS4) combined with recombinant hepatitis B surface antigen (HBsAg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Engerix-B (commercial vaccine)
Number of subjects: 27
Study: 8172748

Group type: EXPERIMENTAL
Intervention: Iotrolan
Number of subjects: 238

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 238
Study: 2738328

Group type: EXPERIMENTAL
Intervention: Cefotetan (2 gr single dose during operation)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 110
Study: 4418439

Group type: EXPERIMENTAL
Intervention: Dorsal position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Left tilt position
Number of subjects: 0
Study: 30587296

Group type: EXPERIMENTAL
Intervention: Pay-it-forward group
Number of subjects: 408

Group type: COMPARATOR
Intervention: Standard-of-care group
Number of subjects: 408
Study: 28789465

Group type: EXPERIMENTAL
Intervention: McKenzie method‐based self‐management approach
Number of subjects: 396

Group type: COMPARATOR
Intervention: Minimal intervention control group
Number of subjects: 396
Study: 24451612

Group type: EXPERIMENTAL
Intervention: Naturopathic approach to CVD prevention (NC+EUC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC; usual care plus biometric screening)
Number of subjects: 0
Study: 23029946

Group type: EXPERIMENTAL
Intervention: Flupirtine maleate 100 mg thrice daily
Number of subjects: 104

Group type: COMPARATOR
Intervention: Tramadol hydrochloride 50 mg thrice daily
Number of subjects: 104
Study: 20491044

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab (1.25 mg) 48 hours before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intravitreal injection (control group)
Number of subjects: 40
Study: 18586222

Group type: EXPERIMENTAL
Intervention: Center-based exercise program (n=11)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (n=12)
Number of subjects: 23
Study: 16082697

Group type: EXPERIMENTAL
Intervention: 5 mg nebulized albuterol
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 5 mg nebulized racemic epinephrine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Nebulized saline placebo
Number of subjects: 65
Study: 11818179

Group type: EXPERIMENTAL
Intervention: Counseling plus behavioral intervention (electronic television time manager)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Counseling alone
Number of subjects: 28
Study: 10402146

Group type: EXPERIMENTAL
Intervention: Counseling attendance and opiate abstinence (week 2)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Opiate-negative urine samples and counseling attendance (week 2)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Submitting two opiate negative urine samples and attending two counseling sessions (week 2)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Early treatment response (week 2)
Number of subjects: 59
Study: 7473480

Group type: EXPERIMENTAL
Intervention: Low impact fitness training
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 73

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 73
Study: 2304505

Group type: EXPERIMENTAL
Intervention: Standard dose of Edmonston-Zagreb vaccine
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Medium dose of Edmonston-Zagreb vaccine
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: High dose of Edmonston-Zagreb vaccine
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Standard dose of Schwarz vaccine
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Medium dose of Schwarz vaccine
Number of subjects: 1061

Group type: COMPARATOR
Intervention: High dose of Schwarz vaccine
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Standard dose of Schwarz vaccine in nine-month-olds
Number of subjects: 1061
Study: 7202858

Group type: EXPERIMENTAL
Intervention: Myo-inositol tablets
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31412825

Group type: EXPERIMENTAL
Intervention: Higher income (quartiles)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Higher relative financial contribution to the household (more than partner)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Contributing more than partner
Number of subjects: 740
Study: 28495343

Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Picture group
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (verbal group)
Number of subjects: 191
Study: 26375471

Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 50
Study: 24252125

Group type: EXPERIMENTAL
Intervention: Practice-level intervention (multifaceted, evidence-based, tailored intervention with a Practice Facilitator)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Patient-level intervention (one-hour visit with a Prevention Practitioner providing a tailored 'prevention prescription')
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Both practice- and patient-level interventions
Number of subjects: 789

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 789
Study: 21234672

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg daily)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 19250820

Group type: EXPERIMENTAL
Intervention: Post-radiation ('maintenance') chemotherapy
Number of subjects: 280

Group type: COMPARATOR
Intervention: Pre-radiation ('sandwich') chemotherapy
Number of subjects: 280
Study: 17503220

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy (SEGT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 16939031

Group type: COMPARATOR
Intervention: Acid/Transbond XT
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Acid/APC Plus
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: TSEP/APC Plus
Number of subjects: 3
Study: 14756454

Group type: EXPERIMENTAL
Intervention: Cooling method B (higher water bolus temperature with extensive head/chest cooling)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cooling method B
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cooling method A (lower water temperature)
Number of subjects: 23
Study: 10367612

Group type: EXPERIMENTAL
Intervention: Mood states (mellow, anxious/annoyed, elated/happy, disengaged/sleepy)
Number of subjects: 154
Study: 9304933

Group type: EXPERIMENTAL
Intervention: Inflation pressure of 4.0-6.6 kPa
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditionally used pressure of 33.3-40.0 kPa
Number of subjects: 52
Study: 1801560

Group type: EXPERIMENTAL
Intervention: Intravenous gamma-globulin (IVGG) at doses of 200 or 400 mg/kg X 5
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous gamma-globulin (IVGG)
Number of subjects: 0
Study: 6218776

Group type: EXPERIMENTAL
Intervention: Superficial acupuncture
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31395096

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise training (HIGH-INT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise training (MOD-INT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-exercise control group (CON)
Number of subjects: 60
Study: 28558833

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide (AB) 400 μg/formoterol fumarate (FF) 12 μg
Number of subjects: 0
Study: 26381519

Group type: EXPERIMENTAL
Intervention: Intravenous rhAPC (24 µg·kg(‐1)·h(‐1))
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23085041

Group type: EXPERIMENTAL
Intervention: 14-week behavioral treatment
Number of subjects: 69
Study: 21501494

Group type: EXPERIMENTAL
Intervention: L-lysine (6 g/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19339794

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16931891

Group type: EXPERIMENTAL
Intervention: Mepolizumab treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 15264973

Group type: EXPERIMENTAL
Intervention: Stimulus control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reinforcement
Number of subjects: 0